Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00729950 · ClinicalTrials.gov registry record · Phase 1
Study of MDX-010 in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 92
- Enrollment target
NCT00729950 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 92 participants.
The verdict
NCT00729950, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 92 participants
- Enrollment target
Study Summary
This is a Phase I, open-label, multicenter, pharmacokinetic study of MDX-010 in up to 90 evaluable subjects with surgically unresectable malignant melanoma.
Interventions
- BIOLOGICAL MDX-010
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2003-07 |
| Est. Completion | 2007-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00729950
The ClinicalTrials.gov registry entry for NCT00729950 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 92 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MDX-010 is the first listed.
NCT00729950 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00729950 about?
NCT00729950 is a clinical study titled "Study of MDX-010 in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma". This is a Phase I, open-label, multicenter, pharmacokinetic study of MDX-010 in up to 90 evaluable subjects with surgically unresectable malignant melanoma.
What is the current status of trial NCT00729950?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 92 participants. The study started on 2003-07. Estimated completion is 2007-06.
What interventions are being tested in trial NCT00729950?
The interventions under investigation include: MDX-010 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00729950?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.